• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2022.17063

The clinical and experimental substantiation of bacteriophages and oxygenated preparation application in disseminated peritonitis complicated with enteral insufficiency

[Original research] [Surgery]
Mikhail Topchiev; Dmitriy Parshin; Misrikhan Misrikhanov; Lev Brusnev; Marat Kazbekovich Chotchaev;

The aim of the study was to investigate the enteral pathobiome and to experimentally substantiate the differentiated use of PT and OD in vitro in AEI. There are 348 bacterial cultures were taken from 116 patients with various stages of AEI (I, II and III) an 2436 isolates of pathogens were isolated. Isolates of Escherichia coli and Enterococcus spp. were triggered in groups I and II, and in group III Klebsiella spp. and Acinetobacter (p<0.05). The use of SF showed good efficiency in AEI I and II Art. The use of BKPP turned out to be effective in AEI III Art. The combined use of polyvalent bacteriophages and OD increased lytic activity in all groups and series of the in vitro experiment. The conducted clinical and experimental study justifies the use of phage therapy in the treatment of the AEI syndrome against the background of WP.

Download

References:
1. Eaton M. D., Bayne-Jones S. Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. Jama. 1934;103(23):1769-1776. https://doi.org/10.1001/jama.1934.72750490003007
2. Abedon S. T., Kuhl S. J., Blasdel B. G., Kutter E. M. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85. https://doi.org/10.4161/bact.1.2.15845
3. Reuter M., Kruger D. H. Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections. Virus Genes. 2020;56:136-149. https://doi.org/10.1007/s11262-020-01735-7
4. Luong T., Salabarria A. C., Dwayne R., Roach D. R. Phage therapy in the resistance era: where do we stand and where are we going? Clinical Therapeutics. 2020;42(9):1659-1680. https://doi.org/10.1016/j.clinthera.2020.07.014
5. Górski A., Jończyk-Matysiak E., Łusiak-Szelachowska M., Międzybrodzki R., Weber-Dąbrowska B. [et al.]. The potential of phage therapy in sepsis. Front. Immunol. 2017;11(8):1783. https://doi.org/10.3389/fi mmu.2017.01783
6. Roach D. R., Debarbieux L. Phage therapy: awakening a sleeping giant. Emerg. Top. Life Sci. 2017;1(1):93-103. https://doi.org/10.1042/ETLS20170002
7. Blanco-Picazo P., Fernández-Orth D., Brown-Jaque M., Miró E., Espinal P. [et al.]. Unravelling the consequences of the bacteriophages in human samples. Sci. Rep. 2020;10:6737. https://doi.org/10.1038/s41598-020-63432-7
8. Shlezinger M., Friedman M., Houri-Haddad Y., Hazan R., Beyth N. Phages in a thermoreversible sustained-release formulation targeting E. faecalis in vitro and in vivo. PLoS ONE. 2019;14(7):e0219599. https://doi.org/10.1371/journal.pone.0219599
9. Racenis K., Kroica J., Rezevska D., Avotins L., Skuditis E. [et al.]. Аureus colonization, biofi lm production, and phage susceptibility in peritoneal dialysis patients. Antibiotics. 2020;9(9):582. https://doi.org/10.3390/antibiotics9090582
10. Kabwe M., Brown T., Speirs L., Ku H., Leach M. [et al.]. Novel bacteriophages capable of disrupting biofi lms from clinical strains of aeromonas hydrophila. Front. Microbiol. 2020;11:194. https://doi.org/10.3389/fmicb.2020.00194
11. Terwilliger A. L., Gu Liu C., Green S. I., Clark J. R., Salazar K. C. [et al.]. Tailored antibacterials and innovative laboratories for phage (Φ) Research: ersonalized infectious disease medicine for the most vulnerable at-risk patients. Phage (New Rochelle). 2020;1(2):66-74. https://doi.org/10.1089/phage.2020.0007
12. Sabino J., Hirten R. P., Colombel J.-F. Review article: bacteriophages in gastroenterology – from biology to clinical applications. Aliment. Pharmacol. Ther. 2020;51:53-63. https://doi.org/10.1111/apt.15557
13. Pires D. P., Monteiro R., Mil-Homens D., Fialho A., Lu T. K. [et al.]. Designing P. aeruginosa synthetic phages with reduced genomes. Sci. Rep. 2021;11:2164. https://doi.org/10.1038/s41598-021-81580-2
14. Abedon S. T., Kuhl S. J., Blasdel B. G., Kutter E. M. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85. https://doi.org/10.4161/bact.1.2.15845
15. Salmond G. P. C., Fineran P. C. A century of the phage: past, present and future. Nature Rev. Microbiol. 2015;13(12):777-786. https://doi.org/10.1038/nrmicro3564
16. Parshin D., Topchiev M., Brusnev L., Emkuzhev K. Proinfl ammatory and antiapoptotic markers of the stages of acute enteral insuffi ciency. Archiv EuroMedica. 2020;10(4):90-93. https://doi.org/10.35630/2199-885X/2020/10/4.22
17. Topchiev M. A., Parshin D. S., Kchibekov E. A., Birukov P. A., Misrikhanov M. K. Diff erentiated approach to antihypoxic and endoportal therapy in treatment of discharged peritonitis complicated by syndrome of intestinal insuffi ciency. Medical News of North Caucasus. 2018;13(4):619-623. (In Russ.). https://doi.org/10.14300/mnnc.2018.13120
18. Topchiev M. A., Parshin D. S., Brusnev L. A., Chotchaev M. K. Possibilities of drug experimental simulation of dynamic intestinal obstruction. Medical News of North Caucasus. 2020;15(3):373-376. (In Russ.). https://doi.org/10.14300/mnnc.2020.15088
19. Gololobov A. M., Melnikov V. V., Topchiev M. A., Parshin D. S. Treatment of anaerobic phlegmon of the upper extremity induced by Clostridium perfringens via application of an oxygenated pharmaceutical. Siberian Med. Rev. 2021;3:107-112.
https://doi.org/10.20333/25000136-2021-3-107-112
20. Malkov I. S., Shakirov M. I., Khalilov Kh. M., Kirshin A. P., Eminov V. L. [et al.]. Method for determining enteric insufficiency in acute intestinal obstruction // RF Patent. Application: 2008109802/14. 2009. Bul. № 29. (In Russ.).
21. Rational use of bacteriophages in medical and anti-epidemic practice. Federal clinical guidelines. Moscow, 2014. Available at: http://nasci.ru/?id=3378&download=1. Accessed September 21, 2021. (In Russ.).
22. El Haddad L., Harb C. P., Gebara M. A., Stibich M. A., Chemaly R. F. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin. Infect. Dis. 2019;69(1):167-178. https://doi.org/10.1093/cid/ciy947
23. Hatfull G. F. Actinobacteriophages: genomics, dynamics, and applications. Ann. Rev. Virol. 2020;7:37-61. https://doi.org/10.1146/annurev-virology-122019-070009
24. Gordillo Altamirano F. L., Barr J. J. Phage Therapy in the Postantibiotic Era. Clin. Microbiol. Rev. 2019;32(2):e00066-18. https://doi.org/10.1128/CMR.00066-18

Keywords: phage therapy, polyvalent bacteriophages, acute enteral failure, widespread peritonitis, enteral pathobiome, oxygenated drugs